Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial

被引：0
|
作者：
Alexander Stein
Albrecht Kretzschmar
Dirk Behringer
Thomas Wolff
Joachim Zimber
Susanna Hegewisch-Becker
Erika Kettner
Karl-Heinz Pflüger
Andreas Kirsch
Dirk Arnold
机构：
[1] University Medical Center,
[2] Hamburg-Eppendorf,undefined
[3] Krankenhaus St Georg,undefined
[4] Augusta-Kranken-Anstalt,undefined
[5] Praxis Lerchenfeld,undefined
[6] Praxis,undefined
[7] Onkologische Schwerpunktpraxis Eppendorf,undefined
[8] University of Magdeburg,undefined
[9] Evangelisches Diakonie-Krankenhaus gGmbH,undefined
[10] Praxis Oskar Helene Heim,undefined
[11] Tumor Biology Center Freiburg,undefined
来源：
BMC Cancer | / 13卷
关键词：
Non-resectable; Metastatic; Colorectal cancer; Capecitabine; Bevacizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial
    Stein, Alexander
    Kretzschmar, Albrecht
    Behringer, Dirk
    Wolff, Thomas
    Zimber, Joachim
    Hegewisch-Becker, Susanna
    Kettner, Erika
    Pflueger, Karl-Heinz
    Kirsch, Andreas
    Arnold, Dirk
    [J]. BMC CANCER, 2013, 13
  • [2] Capecitabine (C) and bevacizumab (B) for nonresectable metastatic colorectal cancer (mCRC) patients: Results from phase II AIO 0105 trial
    Kretzschmar, A.
    Behringer, D. M.
    Wolff, T.
    Zimber, J.
    Hegewisch-Becker, S.
    Kettner, E.
    Pflueger, K.
    Kirsch, A.
    Ziegenhagen, N.
    Arnold, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
    Hoehler, T.
    von Wichert, G.
    Schimanski, C.
    Kanzler, S.
    Moehler, M. H.
    Hinke, A.
    Seufferlein, T.
    Siebler, J.
    Hochhaus, A.
    Arnold, D.
    Hallek, M.
    Hofheinz, R.
    Hacker, U. T.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 109 (06) : 1408 - 1413
  • [4] Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
    T Hoehler
    G von Wichert
    C Schimanski
    S Kanzler
    M H Moehler
    A Hinke
    T Seufferlein
    J Siebler
    A Hochhaus
    D Arnold
    M Hallek
    R Hofheinz
    U T Hacker
    [J]. British Journal of Cancer, 2013, 109 : 1408 - 1413
  • [5] Phase I/II trial of capecitabine (Cap) and oxaliplatin (Ox) in combination with bevacizumab (Bev) and imatinib (Ima) in patients with metastatic colorectal cancer (CRC): AIO KRK 0205
    von Wichert, G.
    Hoehler, T.
    Schimanski, C. C.
    Moehler, M. H.
    Hofheinz, R.
    Kanzler, S.
    Hinke, A.
    Seufferlein, T.
    Siebler, J.
    Hochhaus, A.
    Arnold, D.
    Hallek, M.
    Hacker, U. T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] CHARTA: FOLFOX plus bevacizumab plus /- irinotecan in advanced colorectal cancer (CRC)-Final results of the randomized phase II trial of the AIO (KRK 0209).
    Schmoll, Hans-Joachim
    Garlipp, Benjamin
    Junghanss, Christian
    Leithaeuser, Malte
    Vogel, Arndt
    Schaefers, Michael
    Kaiser, Ulrich
    Hoeffkes, Heinz-Gert
    Florschuetz, Axel
    Ruessel, Joern
    Kanzler, Stephan
    Edelmann, Thomas
    Forstbauer, Helmut
    Goehler, Thomas
    Hannig, Carla
    Hildebrandt, Bert
    Steighardt, Joerg
    Meinert, Fabian Maximilian
    Cygon, Franziska
    Stein, Alexander
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [7] Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC) - Final Results of the phase II AVETUX trial (AIO-KRK-0216)
    Binder, Mascha
    Goekkurt, Eray
    Lorenzen, Sylvie
    Riera-Knorrenschild, Jorge
    Depenbusch, Reinhard
    Ettrich, Thomas
    Doerfel, Steffen
    Al-Batran, Salah
    Karthaus, Meinolf
    Pelzer, Uwe
    Simnica, Donjete
    Waberer, Lisa
    Hinke, Axel
    Bokemeyer, Carsten
    Hegewisch-Becker, Susanna
    Tintelnot, Joseph
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [8] Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216)
    Stein, Alexander
    Binder, Mascha
    Goekkurt, Eray
    Lorenzen, Sylvie
    Riera-Knorrenschild, Jorge
    Depenbusch, Reinhard
    Ettrich, Thomas Jens
    Doerfel, Steffen
    Al-Batran, Salah-Eddin
    Karthaus, Meinolf
    Pelzer, Uwe
    Simnica, Donjete
    Waberer, Lisa
    Hinke, Axel
    Bokemeyer, Carsten
    Hegewisch-Becker, Susanna
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [9] Capecitabine and oxaliplatin (XELOX) in combination with bevacizumab in the treatment of metastatic colorectal cancer: results of a phase II trial
    Bendell, J.
    Yu, D.
    Hurwitz, H.
    Morse, M.
    Blobe, G.
    Gockerman, J.
    Odogwu, L.
    Mahon, M.
    Truax, R.
    Fernando, N.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 189 - 189
  • [10] Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial
    S Stintzing
    L Fischer von Weikersthal
    U Vehling-Kaiser
    M Stauch
    H G Hass
    H Dietzfelbinger
    D Oruzio
    S Klein
    K Zellmann
    T Decker
    M Schulze
    W Abenhardt
    G Puchtler
    H Kappauf
    J Mittermüller
    C Haberl
    C Giessen
    N Moosmann
    V Heinemann
    [J]. British Journal of Cancer, 2011, 105 : 206 - 211
12345